RAPT Therapeutics Inc Cash Flow Conversion Efficiency
RAPT Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) has a cash flow conversion efficiency ratio of -0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.46 Million) by net assets ($151.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of RAPT Therapeutics Inc (2017–2024)
Cash flow conversion efficiency of RAPT Therapeutics Inc from 2017 to 2024. This chart illustrates how RAPT Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RAPT Therapeutics Inc share price for real-time trading data and today's change.
RAPT Therapeutics Inc Cash Flow Conversion Ratio Explained
RAPT Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
RAPT Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RAPT Therapeutics Inc ranked by their cash flow conversion efficiency. Also see RAPT Therapeutics Inc (RAPT) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank of Chongqing Co Ltd
F:CQN
|
-0.075x |
|
Kemper Corporation
NYSE:KMPR
|
-0.012x |
|
Accelevation Holdings Corp. Class A Ordinary Shares
NASDAQ:ACCV
|
-0.420x |
|
Aehr Test Systems
NASDAQ:AEHR
|
0.006x |
|
UroGen Pharma Ltd
NASDAQ:URGN
|
0.249x |
|
Zhejiang Runtu Co Ltd
SHE:002440
|
0.030x |
|
Shaanxi Huaqin Technology Industry Co. Ltd. A
SHG:688281
|
N/A |
|
Fortress Income Fund Ltd
JSE:FFB
|
0.032x |
Annual Cash Flow Conversion Efficiency for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of RAPT Therapeutics Inc from 2017 to 2024. Review RAPT Therapeutics Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $189.90 Million | $-83.30 Million | -0.439x | +33.54% |
| 2023-12-31 | $147.03 Million | $-97.05 Million | -0.660x | -128.65% |
| 2022-12-31 | $245.17 Million | $-70.77 Million | -0.289x | +11.84% |
| 2021-12-31 | $186.38 Million | $-61.03 Million | -0.327x | +15.76% |
| 2020-12-31 | $104.18 Million | $-40.49 Million | -0.389x | +19.89% |
| 2019-12-31 | $73.12 Million | $-35.47 Million | -0.485x | +5.78% |
| 2018-12-31 | $64.00 Million | $-32.95 Million | -0.515x | -218.47% |
| 2017-12-31 | $-62.41 Million | $-27.12 Million | 0.435x | -- |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more